Information Provided By:
Fly News Breaks for March 29, 2018
DXCM
Mar 29, 2018 | 07:48 EDT
Canaccord analyst Kyle Rose raised his price target on Dexcom to $80 from $71 following the early FDA approval of its G6 system. Management's commentary has reinforced his positive sentiment on the approval and its ability to offset any competitive pressure from new entrants. The analyst believes the company is now well positioned against 2018 guidance. Rose reiterated his Buy rating on Dexcom shares.
News For DXCM From the Last 2 Days
There are no results for your query DXCM